Growth Metrics

Verrica Pharmaceuticals (VRCA) Income towards Parent Company (2021 - 2025)

Historic Income towards Parent Company for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to -$308000.0.

  • Verrica Pharmaceuticals' Income towards Parent Company rose 9865.26% to -$308000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.3 million, marking a year-over-year increase of 7147.24%. This contributed to the annual value of -$73.9 million for FY2024, which is 1035.07% down from last year.
  • Latest data reveals that Verrica Pharmaceuticals reported Income towards Parent Company of -$308000.0 as of Q3 2025, which was up 9865.26% from -$393000.0 recorded in Q2 2025.
  • In the past 5 years, Verrica Pharmaceuticals' Income towards Parent Company registered a high of $1.5 million during Q3 2022, and its lowest value of -$24.8 million during Q3 2023.
  • In the last 5 years, Verrica Pharmaceuticals' Income towards Parent Company had a median value of -$10.2 million in 2022 and averaged -$11.0 million.
  • As far as peak fluctuations go, Verrica Pharmaceuticals' Income towards Parent Company soared by 11180.92% in 2022, and later crashed by 173379.54% in 2023.
  • Verrica Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$9.5 million in 2021, then skyrocketed by 37.89% to -$5.9 million in 2022, then crashed by 316.02% to -$24.6 million in 2023, then soared by 45.01% to -$13.6 million in 2024, then surged by 97.73% to -$308000.0 in 2025.
  • Its Income towards Parent Company stands at -$308000.0 for Q3 2025, versus -$393000.0 for Q2 2025 and -$10.0 million for Q1 2025.